FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074456535> ?p ?o ?g. }

• W2074456535 endingPage "57" @default.
• W2074456535 startingPage "49" @default.
• W2074456535 abstract "Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated.Multicenter, double-blind, randomized, controlled trial.53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients).Pentoxifylline (400mg/d; n=26) or matching placebo (control; n=27) for 4 months.ESA resistance index at 4 months; secondary outcomes: hemoglobin concentration, ESA dose, blood transfusion requirement, serum ferritin level and transferrin saturation, C-reactive protein level, adverse events, quality of life, and health economics.There was no statistically significant difference in ESA resistance index between the pentoxifylline and control groups (adjusted mean difference, -0.39 [95%CI, -0.89 to 0.10] IU/kg/wk/g/L; P=0.1). Pentoxifylline significantly increased hemoglobin concentration relative to the control group (adjusted mean difference, 7.6 [95%CI, 1.7-13.5] g/L; P=0.01). There was no difference in ESA dose between groups (-20.8 [95%CI, -67.2 to 25.7] IU/kg/wk; P=0.4). No differences in blood transfusion requirements, adverse events, or quality of life were observed between groups. Pentoxifylline cost A$88.05 (US $82.94) per person over the trial and produced mean savings in ESA cost of A$1,332 (US $1,255). The overall economic impact over the trial period was a saving of A$1,244 (US $1,172) per person for the pentoxifylline group compared with controls.Sample size smaller than planned due to slow recruitment.Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia." @default.
• W2074456535 created "2016-06-24" @default.
• W2074456535 creator A5001559641 @default.
• W2074456535 creator A5005714071 @default.
• W2074456535 creator A5014293204 @default.
• W2074456535 creator A5024768204 @default.
• W2074456535 creator A5025231262 @default.
• W2074456535 creator A5027520502 @default.
• W2074456535 creator A5028934357 @default.
• W2074456535 creator A5038007882 @default.
• W2074456535 creator A5043394711 @default.
• W2074456535 creator A5058313936 @default.
• W2074456535 creator A5065040397 @default.
• W2074456535 creator A5069484787 @default.
• W2074456535 creator A5075474387 @default.
• W2074456535 creator A5078953009 @default.
• W2074456535 creator A5080872947 @default.
• W2074456535 creator A5087336965 @default.
• W2074456535 date "2015-01-01" @default.
• W2074456535 modified "2023-09-30" @default.
• W2074456535 title "A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial" @default.
• W2074456535 cites W1543736630 @default.
• W2074456535 cites W1976510563 @default.
• W2074456535 cites W1980042430 @default.
• W2074456535 cites W1992880469 @default.
• W2074456535 cites W1998943227 @default.
• W2074456535 cites W2025063713 @default.
• W2074456535 cites W2038073583 @default.
• W2074456535 cites W2046124938 @default.
• W2074456535 cites W2046224330 @default.
• W2074456535 cites W2058851478 @default.
• W2074456535 cites W2059080581 @default.
• W2074456535 cites W2097586983 @default.
• W2074456535 cites W2099867389 @default.
• W2074456535 cites W2103922704 @default.
• W2074456535 cites W2114572286 @default.
• W2074456535 cites W2117616342 @default.
• W2074456535 cites W2120939456 @default.
• W2074456535 cites W2125273284 @default.
• W2074456535 cites W2129312245 @default.
• W2074456535 cites W2132493462 @default.
• W2074456535 cites W2133256067 @default.
• W2074456535 cites W2138222693 @default.
• W2074456535 cites W2141434615 @default.
• W2074456535 cites W2156457843 @default.
• W2074456535 cites W2168246852 @default.
• W2074456535 cites W2169284885 @default.
• W2074456535 cites W4249150518 @default.
• W2074456535 cites W4292806894 @default.
• W2074456535 doi "https://doi.org/10.1053/j.ajkd.2014.06.020" @default.
• W2074456535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25115616" @default.
• W2074456535 hasPublicationYear "2015" @default.
• W2074456535 type Work @default.
• W2074456535 sameAs 2074456535 @default.
• W2074456535 citedByCount "30" @default.
• W2074456535 countsByYear W20744565352015 @default.
• W2074456535 countsByYear W20744565352016 @default.
• W2074456535 countsByYear W20744565352017 @default.
• W2074456535 countsByYear W20744565352018 @default.
• W2074456535 countsByYear W20744565352019 @default.
• W2074456535 countsByYear W20744565352020 @default.
• W2074456535 countsByYear W20744565352021 @default.
• W2074456535 countsByYear W20744565352022 @default.
• W2074456535 countsByYear W20744565352023 @default.
• W2074456535 crossrefType "journal-article" @default.
• W2074456535 hasAuthorship W2074456535A5001559641 @default.
• W2074456535 hasAuthorship W2074456535A5005714071 @default.
• W2074456535 hasAuthorship W2074456535A5014293204 @default.
• W2074456535 hasAuthorship W2074456535A5024768204 @default.
• W2074456535 hasAuthorship W2074456535A5025231262 @default.
• W2074456535 hasAuthorship W2074456535A5027520502 @default.
• W2074456535 hasAuthorship W2074456535A5028934357 @default.
• W2074456535 hasAuthorship W2074456535A5038007882 @default.
• W2074456535 hasAuthorship W2074456535A5043394711 @default.
• W2074456535 hasAuthorship W2074456535A5058313936 @default.
• W2074456535 hasAuthorship W2074456535A5065040397 @default.
• W2074456535 hasAuthorship W2074456535A5069484787 @default.
• W2074456535 hasAuthorship W2074456535A5075474387 @default.
• W2074456535 hasAuthorship W2074456535A5078953009 @default.
• W2074456535 hasAuthorship W2074456535A5080872947 @default.
• W2074456535 hasAuthorship W2074456535A5087336965 @default.
• W2074456535 hasConcept C126322002 @default.
• W2074456535 hasConcept C141071460 @default.
• W2074456535 hasConcept C142724271 @default.
• W2074456535 hasConcept C153852466 @default.
• W2074456535 hasConcept C168563851 @default.
• W2074456535 hasConcept C197934379 @default.
• W2074456535 hasConcept C204787440 @default.
• W2074456535 hasConcept C27081682 @default.
• W2074456535 hasConcept C2777417653 @default.
• W2074456535 hasConcept C2778248108 @default.
• W2074456535 hasConcept C2778534260 @default.
• W2074456535 hasConcept C2778653478 @default.
• W2074456535 hasConcept C2778917026 @default.
• W2074456535 hasConcept C2779703530 @default.
• W2074456535 hasConcept C2780404050 @default.
• W2074456535 hasConcept C2780959883 @default.
• W2074456535 hasConcept C71924100 @default.

• next